PMID- 2032716
OWN - NLM
STAT- MEDLINE
DCOM- 19910627
LR  - 20190503
IS  - 0266-4348 (Print)
IS  - 0266-4348 (Linking)
VI  - 67
IP  - 2
DP  - 1991 Apr
TI  - Systemic interferon alpha-2b increases the cure rate in laser treated patients 
      with multiple persistent genital warts: a placebo-controlled study.
PG  - 99-102
AB  - Systemic treatment modalities for eradication of multiple therapy resistant 
      genital warts are so far not available. In this study laser treated patients with 
      multiple genital warts received postoperatively either interferon alpha-2b 
      subcutaneously (s.c.) 5 x 10(6) IU or matching placebo three times weekly for 
      four weeks. At the conclusion of the study, 6-8 weeks after discontinuation of 
      therapy, a significantly higher cure rate was found in the group of 
      interferon-treated patients (14 of 27 (52%) patients cured) than among placebo 
      treated patients (5 of 22 (23%) patients cured) (p less than 0.05). The side 
      effects of fever, chills, myalgia, headache and leukopenia occurred more commonly 
      in the interferon treated group than in the placebo group. However, only three of 
      32 patients discontinued interferon therapy because of side effects. We conclude 
      that the addition of s.c. administered interferon alpha-2b to laser treated 
      patients with chronic therapy resistant genital warts is fairly well tolerated 
      and that it significantly enhances the chance of eliminating the disease.
FAU - Petersen, C S
AU  - Petersen CS
AD  - Department of Dermatology and Venereology, Bispebjerg Hospital, University of 
      Copenhagen, Denmark.
FAU - Bjerring, P
AU  - Bjerring P
FAU - Larsen, J
AU  - Larsen J
FAU - Blaakaer, J
AU  - Blaakaer J
FAU - Hagdrup, H
AU  - Hagdrup H
FAU - From, E
AU  - From E
FAU - Obergaard, L
AU  - Obergaard L
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Genitourin Med
JT  - Genitourinary medicine
JID - 8503853
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (Recombinant Proteins)
SB  - IM
MH  - Adult
MH  - Combined Modality Therapy
MH  - Condylomata Acuminata/*therapy
MH  - Female
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Interferon alpha-2
MH  - Interferon-alpha/*administration & dosage/therapeutic use
MH  - *Laser Therapy
MH  - Male
MH  - Penile Neoplasms/*therapy
MH  - Recombinant Proteins
MH  - Vaginal Neoplasms/*therapy
PMC - PMC1194640
EDAT- 1991/04/01 00:00
MHDA- 1991/04/01 00:01
PMCR- 1991/04/01
CRDT- 1991/04/01 00:00
PHST- 1991/04/01 00:00 [pubmed]
PHST- 1991/04/01 00:01 [medline]
PHST- 1991/04/01 00:00 [entrez]
PHST- 1991/04/01 00:00 [pmc-release]
AID - 10.1136/sti.67.2.99 [doi]
PST - ppublish
SO  - Genitourin Med. 1991 Apr;67(2):99-102. doi: 10.1136/sti.67.2.99.